FDA expands Isturisa approval to all forms of endogenous Cushing’s
The U.S. Food and Drug Administration (FDA) has approved Isturisa (osilodrostat) to treat adults with all forms of endogenous Cushing’s syndrome for whom surgery is not an option or has not been curative. This marks an expansion of the approved indication for Isturisa, which had previously been cleared only…